Prime Capital Investment Advisors LLC Boosts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Prime Capital Investment Advisors LLC raised its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 42.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 9,168 shares of the biopharmaceutical company’s stock after purchasing an additional 2,743 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Intra-Cellular Therapies were worth $657,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Intra-Cellular Therapies by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 8,539,725 shares of the biopharmaceutical company’s stock valued at $444,834,000 after buying an additional 43,689 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Intra-Cellular Therapies by 13.1% in the 1st quarter. BlackRock Inc. now owns 6,470,417 shares of the biopharmaceutical company’s stock valued at $395,924,000 after buying an additional 748,651 shares in the last quarter. Wellington Management Group LLP bought a new stake in shares of Intra-Cellular Therapies in the 1st quarter valued at about $248,502,000. State Street Corp boosted its holdings in shares of Intra-Cellular Therapies by 3.9% in the 2nd quarter. State Street Corp now owns 2,105,705 shares of the biopharmaceutical company’s stock valued at $133,333,000 after buying an additional 79,477 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Intra-Cellular Therapies by 4.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,063,802 shares of the biopharmaceutical company’s stock valued at $107,503,000 after buying an additional 86,388 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Trading Down 2.0 %

Shares of NASDAQ ITCI opened at $67.28 on Thursday. Intra-Cellular Therapies, Inc. has a 12 month low of $45.50 and a 12 month high of $76.11. The company has a 50 day simple moving average of $69.06 and a two-hundred day simple moving average of $63.21. The stock has a market cap of $6.51 billion, a price-to-earnings ratio of -46.08 and a beta of 1.02.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.14. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The business had revenue of $132.10 million during the quarter, compared to analysts’ expectations of $135.97 million. During the same period in the previous year, the business posted ($0.45) EPS. The business’s quarterly revenue was up 50.3% compared to the same quarter last year. Analysts forecast that Intra-Cellular Therapies, Inc. will post -0.65 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on ITCI shares. Mizuho raised their price target on shares of Intra-Cellular Therapies from $76.00 to $82.00 and gave the company a “buy” rating in a report on Friday, February 16th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $101.00 target price on shares of Intra-Cellular Therapies in a research note on Friday, February 23rd. The Goldman Sachs Group lifted their target price on shares of Intra-Cellular Therapies from $58.00 to $64.00 and gave the stock a “neutral” rating in a research note on Thursday, January 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $86.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, April 3rd. Finally, Bank of America lifted their target price on shares of Intra-Cellular Therapies from $74.00 to $82.00 and gave the stock a “buy” rating in a research note on Tuesday, January 2nd. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.42.

Insider Activity

In other news, CEO Sharon Mates sold 22,590 shares of Intra-Cellular Therapies stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $69.79, for a total transaction of $1,576,556.10. Following the completion of the transaction, the chief executive officer now directly owns 1,050,309 shares of the company’s stock, valued at approximately $73,301,065.11. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Sharon Mates sold 22,590 shares of Intra-Cellular Therapies stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $69.79, for a total transaction of $1,576,556.10. Following the completion of the transaction, the chief executive officer now directly owns 1,050,309 shares of the company’s stock, valued at approximately $73,301,065.11. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Suresh K. Durgam sold 6,450 shares of Intra-Cellular Therapies stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $66.56, for a total transaction of $429,312.00. Following the transaction, the executive vice president now directly owns 16,170 shares of the company’s stock, valued at $1,076,275.20. The disclosure for this sale can be found here. Insiders sold a total of 311,765 shares of company stock valued at $20,860,487 in the last three months. 3.40% of the stock is currently owned by corporate insiders.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.